Request Demo

Last update 08 May 2025

Atypical Lobular Breast Hyperplasia

Last update 08 May 2025

Basic Info

Synonyms

ALH, Atypical Breast Lobular Hyperplasia, Atypical Lobular Breast Hyperplasia

+ [11]

Introduction

Lobular neoplasia characterized by lobular epithelial proliferation that does not completely fill the lobular unit of the breast.

Drugs associated with Atypical Lobular Breast Hyperplasia

Afimoxifene

Target

Mechanism

ERs modulators

Active Org.

National Cancer Institute

Originator Org.

National Cancer Institute

Active Indication

Atypical Lobular Breast Hyperplasia [+3]

Inactive Indication

Estrogen receptor positive breast cancer [+1]

Drug Highest PhasePhase 2

First Approval Ctry. / Loc.-

First Approval Date20 Jan 1800

Clinical Trials associated with Atypical Lobular Breast Hyperplasia

NCT05178498

/ RecruitingNot ApplicableIIT

Longitudinal Study Evaluating the Impact of Dietary Inflammatory Potential on Breast Cancer Risk in a Cohort of Women Followed in the Breast Cancer Prevention Clinic at the Ohio State University Comprehensive Cancer Center- James Cancer Hospital and Solove Research Institute

This study evaluates the association of dietary inflammatory potential with breast cancer risk. Information collected in this study may help doctors to identify modifiable risk factors, screen high risk patients early, improve prevention strategies, and provide timely intervention for early therapeutic management as needed.

Start Date25 Oct 2023

Sponsor / Collaborator

Ohio State University Comprehensive Cancer Center

NCT05755269

/ RecruitingNot ApplicableIIT

Genetic Risk Estimation in Breast Cancer and Assessing Health Disparities

This study evaluates whether adding a polygenic risk score evaluation to standard breast cancer risk assessment tools helps African American and Hispanic women make more informed decisions about accepting additional breast cancer screening and prevention strategies. Traditional breast cancer risk assessments rely mostly on the presence of standard clinical risk factors including family history, reproductive history, and mammographic breast density. This information can be combined with validated risk estimation models to provide a measure of a patient's 10 year and lifetime risk for breast cancer. A polygenic risk score helps to estimate breast cancer risk in a more individualized way by evaluating a patient's genetics. Adding a polygenic risk score evaluation to traditional screening techniques may help minority women make more informed decisions about screening and prevention strategies for breast cancer.

Start Date14 Mar 2023

Sponsor / Collaborator

Mayo Clinic

ChiCTR2100048029

/ SuspendedNot ApplicableIIT

An open, single-arm design clinical trial on the treatment of hyperplasia of mammary gland by Yin and Yang double acupoint method

Start Date01 Sep 2021

Sponsor / Collaborator-

100 Clinical Results associated with Atypical Lobular Breast Hyperplasia

100 Translational Medicine associated with Atypical Lobular Breast Hyperplasia

0 Patents (Medical) associated with Atypical Lobular Breast Hyperplasia

220

Literatures (Medical) associated with Atypical Lobular Breast Hyperplasia

01 May 2025·Journal of Clinical and Experimental Hepatology

Drug-induced Autoimmune-like Hepatitis With Pathological Features of Giant Cell Hepatitis

Article

Author: Lin, Haiyan ; Ruan, Mei ; Yan, Yongqin ; Zeng, Zhiyu ; Yao, Jie ; Li, Dongliang

Background and methodsThe differentiation between drug-induced autoimmune-like hepatitis (DI-ALH) and autoimmune hepatitis (AIH) can be confusing and challenging. We present a case of DI-ALH characterized by positive autoantibodies, elevated immunoglobulin G (IgG) levels and histology characteristics of giant cell hepatitis.ResultsA liver biopsy was performed for etiology clarification, DI-ALH was diagnosed. Following treatment with corticosteroids and azathioprine, the patient's liver function remained normal without recurrence.ConclusionsDistinguishing DI-ALH from AIH based on the possibility of discontinuing immunosuppression and the histological features. Clinicians need to investigate patient's medical history, serological tests, and pathological changes to establish a correct diagnosis.

01 May 2025·AIDS

Outcomes and challenges in adolescents with HIV in France: a nationwide cohort study over 35 years

Article

Author: Frange, Pierre ; Blanche, Stéphane ; Caseris, Marion ; Le Chenadec, Jérôme ; Faye, Albert ; Dollfus, Catherine ; Runel-Belliard, Camille ; Alby-Laurent, Fanny ; Reliquet, Véronique ; Warszawski, Josiane ; Brehin, Camille

Objective:Most data published on adolescents with HIV (AWH) have been collected before the large diffusion of second-generation integrase strand transfer inhibitors (INSTI) among the pediatric population. We analyzed the nationwide ANRS-MIE CO10 Pediatric cohort to assess the changes over time in health and social outcomes of French AWH.Design:The cohort enrolled children born in France since 1985 and, from 2005, children diagnosed with HIV at ≤13 years, including those born abroad if antiretroviral-naive at first medical care in France.Methods:Adolescents aged ≥10 years at their last visit were included in this analysis. Their characteristics were compared between three periods of birth (1985–1993, 1994–1999, 2000–2010).Results:Overall, 529 AWH were included. Their median age at first HAART initiation decreased from 94 to 29 months (P < 0.0001). At the last evaluation, the proportions of AWH receiving HAART, receiving INSTI, having HIV-RNA < 50 copies/mL and having CD4 count ≥500/μl increased over time (P < 0.0001), reaching 98·7%, 53.3%, 81.3% and 85·0%, respectively, for those born in 2000–2010. The proportion of maternal and paternal orphans decreased until 14.4% and 11.0%, respectively, for AWH born recently. Compared to middle adolescents (15–17 years) born in 1994–1999, those born in 2000–2010 demonstrated higher academic success (69·2% versus 42·3%) and less frequent academic failure (4.6% versus 6.2%).Conclusions:Despite spectacular improvement in their health and immunovirological status, AWH remain vulnerable compared to other French adolescents, with a higher risk of being orphan and/or experiencing academic failure. Specific interventions are required to improve their global quality of life.

01 Apr 2025·Breast Cancer Research and Treatment

Breast hamartomas associated with epithelial atypia and malignancy: are there specific clinical, radiological or pathological features that identify at risk patients?

Article

Author: Dani, Shefali ; Tariq, Naima ; Warren, Madhuri V ; Makhija, Purnima

PURPOSEBreast hamartomas are rarely associated with epithelial atypia or malignancy. Since the introduction of digital mammography in the UK from 2008, hamartoma detection has increased. The aim of this study was to identify if there are characteristic clinical, radiological or histological features that distinguish hamartomas with intralesional atypia/malignancy (complex hamartomas, CH) or ipsilateral/contralateral atypia/malignancy (non-CH) from those without atypia/malignancy at diagnosis (other benign hamartomas, BH).METHODSWe performed a retrospective single-institution review of 450 hamartomas reported between 2010 and 2023. Anonymised H&E sections and imaging of CH and non-CH were reviewed to identify distinguishing features.RESULTS13,441 benign breast lesions were biopsied/resected between 2010 and 2023 including 450 hamartomas (3.3%), 19 of which (4.2%) were associated with atypia or malignancy. 14 were analysed further (7 CH; 7 non-CH). The mean age of CH plus non-CH patients was significantly higher than patients with BH (47.5 vs. 40.6 years; p = 0.03). The mean size of CH was greater than non-CH (32.1 mm vs.17.6 mm; p = 0.06). There was a statistically significantly higher incidence of atypical/malignant lobular lesions (ALH/LCIS/ILC) in CH vs. non-CH (42.9% vs 0%; p = 0.05). MRI was performed in 2 CH and 3 non-CH; in all 5 the associated malignancy was detected. There was no significant difference between the CH and non-CH group in ultrasound/mammographic features, other hamartoma histological features or other associated benign breast changes.CONCLUSIONSUltrasound/mammogram are not sufficiently sensitive to identify hamartomas with associated atypia/malignancy. Certain hamartoma features may preferentially be associated with atypia/malignancy and which merit further radiological and/or detailed histological investigation.

Analysis

Perform a panoramic analysis of this field.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Atypical Lobular Breast Hyperplasia

Basic Info

Related

Analysis